Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms

Inclusion Criteria

• Signed informed consent;
• Patients over the age of 18;
• Recently confirmed mucinous cystic pancreatic neoplasm; may be confirmed by presence of mucin, cyst fluid carcinoembryonic antigen (CEA) above 192 U/L, or other reliable diagnostic means such as endomicroscopy; KRAS analysis may also be performed at the discretion of the Investigator;
• Unilocular cyst with diameter of at least 1.5 cm but no more than 4 cm;
• Normal hematologic, hepatic, and renal function at study entry;
• Appropriate steps taken to minimize or avoid the potential for pregnancy for subjects of child-bearing potential.*
• Note: A female patient is considered to be of childbearing potential unless she has had a hysterectomy, is at least one year postmenopausal or has undergone tubal ligation. For the purposes of this study, adequate birth control includes at least one medically approved and highly effective method of birth control, defined as those which result in a low failure rate (i.e., < 1% per year) when used consistently and correctly, such as implants, injectables and oral contraceptives combined with the use of condoms. Only male patients whose vasectomy has been confirmed by semen analysis at least 3 months after the vasectomy are allowed not to use acceptable contraceptive methods.

Exclusion Criteria

• Positive cytology indicating malignancy;
• Thrombotic or embolic events;
• Known hypersensitivity to study agent;
• Known drug or alcohol abuse;
• Pregnant or breastfeeding women.